Idogen has recruited Dr. Steven Glazer to the position of Chief Medical Officer (CMO) commencing the 1st of April.
The company hopes that this appointment means a strengthening of the organization for future clinical studies, initially in hemophilia A.
“I look forward to working with Idogen and hemophilia again – a patient group I’ve worked a lot with. Idogen has an interesting technology which can change the current treatment modality of medically very vulnerable patients and I think my previous experiences will be useful,” said Steven Glazer.
Steven Glazer’s most recent role was as CMO at Hansa Medical. He has an extensive experience from senior positions in clinical drug development. His previous assignments include Senior Vice President of Development at BioInvent, Vice President of Development at Zealand Pharma and Medical Director at Novo Nordisk. He has extensive industrial experience in several therapeutic areas important for Idogen, including hemophilia, hematology, transplantation and diabetes. Steven has a doctorate in medicine from the University of Copenhagen and is trained in internal medicine.
”The recruitment of Steven Glazer as Chief Medical Officer means a considerable strengthening of Idogen’s competence and is very much in line with the aim for the upcoming clinical trials. Steven’s extensive experience in the development of new treatments in hemophilia will be a great asset for us,” said CEO Lars Hedbys.
Photo: Kennet Rouna